THX Pharma (formerly Theranexus) is an innovative biopharmaceutical company that emerged from the French Atomic Energy Commission (CEA) and specializes in the treatment of neurological diseases and pioneer in the development of drug candidates targeting both neurons and glial cells. THX Pharma has a unique platform for the identification and characterization of innovative therapy drug candidates in rare neurological disorders and a first drug candidate in clinical development for Batten disease.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change
05/10/26	€3.060	-7.41%
02/10/26	€3.305	-0.15%
01/10/26	€3.310	-3.64%
30/09/26	€3.435	+4.41%
29/09/26	€3.290	-0.45%

Delayed Quote Deutsche Boerse AG

More quotes

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

3.160EUR

Average target price

5.800EUR

Spread / Average Target

+83.54%

Consensus

Annual profits - Rate of surprise

Company calendar

Real-time Estimate Cboe Europe 18:40:00 05/10/2026 +03			5-day change	1st Jan Change
3.120 ^EUR	-5.60%		-7.41%	+53.00%

09-29	THX Pharma Société Anonyme Reports Earnings Results for the Half Year Ended June 30, 2026	CI
09-02	THX Pharma Partnership Seeks Regulatory Clearance for Late-stage Juvenile Batten Disease Drug Trial	MT

Market Cap	43.6M 48.87M 40.62M 36.96M 69.61M 4.71B 70.12M 491M 191M 2.4B 183M 180M 7.72B	P/E 2026 *	-	P/E 2027 *	-
Enterprise Value	19.9M 22.3M 18.54M 16.87M 31.77M 2.15B 32M 224M 87.14M 1.1B 83.73M 81.92M 3.52B	EV / Sales 2026 *	-	EV / Sales 2027 *	-
Free-Float	89.81%	Yield 2026 *	-	Yield 2027 *	-

Markets		Quality
Euronext Paris	ALTHX	Real-time
CBOE		Real-time
Boerse Muenchen	3VG	Real-time
Börse Stuttgart	3VG	Delayed
Deutsche Boerse AG	3VG	Delayed
CBOE		Real-time

09-29	THX Pharma Société Anonyme Reports Earnings Results for the Half Year Ended June 30, 2026	CI
09-02	THX Pharma Partnership Seeks Regulatory Clearance for Late-stage Juvenile Batten Disease Drug Trial	MT
09-01	THX Pharma Submits Regulatory Applications To Initiate Phase 3 Clinical Trial Of Batten-1 In Juvenile Batten Disease	CI
07-09	THX Pharma secures its financial roadmap
06-23	THX Pharma appoints Sophie Jacq Lapointe to its board of directors
06-23	THX Pharma Announces Appointment of Sophie Jacq Lapointe to Board of Directors	CI
06-10	THX Pharma, Exeltis Receive Positive EU Opinion for TX01 Pediatric Investigation Plan	MT
06-09	THX Pharma And Exeltis Secure EMA Approval Of The Paediatric Investigation Plan For TX01 Unlocking The PUMA Registration Pathway	CI
06-09	EMA grants pediatric green light for THX Pharma's TX01
05-16	Certain Shares of THX Pharma Société Anonyme are subject to a Lock-Up Agreement Ending on 16-MAY-2026.	CI
04-28	THX Pharma Société Anonyme Reports Earnings Results for the Full Year Ended December 31, 2025	CI
02-20	Air Liquide, Danone, Parrot... Key Stocks to Watch Today in Paris
02-19	Imerys, GTT, Louis Hachette Group... Key Stocks to Watch Tomorrow in Paris

THX Pharma Stock Deutsche Boerse AG

Stocks

3VG

FR0013286259

Biotechnology & Medical Research

Valuation: THX Pharma

Chart: THX Pharma

Latest news: THX Pharma

Press Releases: THX Pharma

News in other languages: THX Pharma

Quotes and Performance

Price Extremes

Managers and Directors: THX Pharma

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Analysts' Consensus

Annual profits - Rate of surprise

09-29	Thx Pharma : THX PHARMA REPORTS ITS FINANCIAL RESULTS FOR THE FIRST HALF OF 2026	AT
09-09	Thx Pharma : Corrected press release : THX Pharma and the Beyond Batten Disease Foundation Announce the Grant of a European Patent Protecting the Use of Batten-1 in Juvenile Batten Disease (CLN3)	AT
09-08	Thx Pharma : THX Pharma and the Beyond Batten Disease Foundation Announce the Grant of a European Patent Protecting the Use of Batten-1 in Juvenile Batten Disease (CLN3)	AT
09-01	Thx Pharma : THX Pharma, BBDF and Biocodex Announce Regulatory Submissions for the Phase 3 Clinical Trial of Batten-1 in Juvenile Batten Disease (CLN3)	AT
07-09	Thx Pharma : THX Pharma Reports Cash Position as of June 30, 2026	AT

09-29	THX Pharma réduit fortement sa perte au premier semestre et renforce sa trésorerie
09-29	Thx Pharma : THX PHARMA ANNONCE SES RESULTATS FINANCIERS DU PREMIER SEMESTRE 2026
09-29	Bourse : Legrand veut sa part d'IA, Lindt avertit, Shein coule
09-29	L'obligataire fait monter la pression
09-28	Agenda Zonebourse des résultats de sociétés : semaine du 28 septembre au 2 octobre 2026

1 day	-5.60%
1 week	-7.41%
Current month	-10.92%
1 month	-17.07%
3 months	-14.76%
6 months	+1.83%
Current year	+53.00%

1 week	3.06	3.44
1 month	3.06	3.87
Current year	1.84	4.49
1 year	1.51	4.49
3 years	0.36	4.49
5 years	0.36	7.53
10 years	0.36	21.5

Manager	Title	Age	Since
Mathieu Bernard Mari Charveriat CEO	Chief Executive Officer	-	01/01/2023
Christine Placet DFI	Director of Finance/CFO	-	01/04/2024
Marie Sebille CTO	Chief Tech/Sci/R&D Officer	-	19/10/2021

Director	Title	Age	Since
Franck Joseph Mouthon BRD	Director/Board Member	-	31/03/2024
Mathieu Bernard Mari Charveriat CHM	Chairman	-	31/03/2024
Julien Veys BRD	Director/Board Member	-	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
THX PHARMA	-5.60%	-7.41%	-	-	49.07M
WUXI APPTEC CO., LTD.	+4.16%	+3.04%	+49.37%	+94.17%	74.16B
ARGENX SE	-0.37%	-3.81%	+19.51%	+78.12%	57.39B
LONZA GROUP AG	+1.63%	-1.61%	+3.16%	+36.89%	47.64B
REVOLUTION MEDICINES, INC.	-1.02%	+1.52%	+339.71%	+710.83%	44.29B
IQVIA HOLDINGS INC.	+2.03%	-2.84%	+28.41%	+33.09%	42.5B
BEONE MEDICINES AG	+0.48%	-2.14%	+4.24%	+110.42%	40.71B
CELLTRION, INC.	-0.54%	+2.93%	+9.31%	+54.06%	30.97B
WUXI BIOLOGICS (CAYMAN) INC.	+1.56%	+4.53%	+31.34%	+26.92%	28.53B
BIONTECH SE	+0.06%	-2.45%	-8.09%	-12.02%	24.34B
Average	+0.20%	-0.59%	+52.99%	+125.83%	43.39B
Weighted average by Cap.	+1.12%	-0.84%	+57.21%	+135.10%

	2026 *	2027 *
Net sales	-	-
Net income	11.9M 13.34M 11.09M 10.09M 19M 1.28B 19.14M 134M 52.12M 656M 50.08M 49M 2.11B	4.3M 4.82M 4.01M 3.65M 6.87M 464M 6.92M 48.41M 18.83M 237M 18.09M 17.7M 762M
Net Debt	-23.7M -26.57M -22.08M -20.09M -37.84M -2.56B -38.12M -267M -104M -1.31B -99.73M -97.58M -4.2B	-27.4M -30.71M -25.53M -23.23M -43.75M -2.96B -44.07M -308M -120M -1.51B -115M -113M -4.85B